33 research outputs found
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study
Full text linkEvaluation of chromosomal abnormalities by cIg-FISH and association with proliferative and apoptotic indexes in multiple myeloma
Full text linkFDG-PET in Follicular Lymphoma Management
No full text18-Fluoro-deoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) is commonly used in the management of patients with lymphomas and is recommended for both initial staging and response assessment after treatment in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Despite the FDG avidity of follicular lymphoma (FL), FDG PET/CT is not yet applied in standard clinical practice for patients with FL. However, FDG PET/CT is more accurate than conventional imaging for initial staging, often prompting significant management change, and allows noninvasive characterization to guide assessment of high-grade transformation. For restaging, FDG PET/CT assists in distinguishing between scar tissue and viable tumors in residual masses and a positive PET after induction treatment would seem to predict a shorter progression-free survival
Arrêt de l’antibiothérapie en cours de neutropénie pour fièvre d’origine indéterminée en hématologie stérile : RELAPS, une étude de cohorte bicentrique descriptive
No full textImpact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
No full textInternational audienceno abstrac
16S RNA Gene Pyrosequencing Reveals Shift in Patient Fecal Microbiota during High Dose Chemotherapy as Conditioning Regimen for Bone Marrow Transplantation
Full text linkClassical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant
No full textSecond-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier
No full textRituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
No full textInternational audienceWe retrospectively evaluated the role of rituximab (R) in maintenance treatment after autologous stem cell transplantationperformed in patients with relapsed follicular lymphoma. We compared the outcome of 67 follicular lymphoma (FL) patients according to the use of rituximab maintenance (RM) or not. All patients received rituximab plus chemotherapy before autologous stem-cell transplantation (ASCT). Patients received median of two lines of prior therapy. The RM schedule was one injection of rituximab every 3 months for 2 years. Median follow-up is 4.6 years. The 3-year progression-free survival (PFS) after ASCT was 86 % with RM vs. 46 % without (p = 0.0045). Median is not reached in the RM arm vs. 31 months in non-RM arm. The 3-year OS was 96 % with RM vs. 78 % without (p = 0.059). The present monocentric study shows that 2 years of RM after ASCT significantly increases response duration for non-naive rituximab relapsed FL patients compared with observation
